Pacific Biosciences Acquires Omniome
July 20, 2021
Pacific Biosciences (PacBio) signed a definitive agreement to acquire San Diego-based Omniome for approximately $600 million in upfront consideration (9.4 million PacBio shares plus $300 million cash) plus up to $200 million in cash and stock tied to milestones, valuing the deal at about $800 million. The deal — supported by a concurrent $300 million PIPE financing — brings Omniome’s high-accuracy short-read Sequencing-by-Binding technology into PacBio’s portfolio of high-accuracy long-read SMRT sequencing systems to expand PacBio’s capabilities and address high-growth clinical markets such as oncology, transcriptomics and NIPT.
- Buyers
- Pacific Biosciences of California, Inc. (PacBio)
- Targets
- Omniome
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Illumina Acquires SomaLogic from Standard BioTools
January 30, 2026
Healthcare Services
Illumina, Inc. completed its acquisition of SomaLogic, adding data-driven proteomics technology to expand its multiomics portfolio. The deal was for $350 million in upfront cash at closing, plus up to $75 million in near-term performance-based milestones/royalties, with Illumina expecting to fund the transaction with cash on hand.
-
10x Genomics to Acquire Scale Biosciences
August 7, 2025
Healthcare Services
10x Genomics, Inc. has signed a definitive agreement to acquire Scale Biosciences, Inc., a single-cell analysis company. The deal is intended to expand 10x’s Chromium platform with Scale’s key inventions and technologies and broaden access to scalable single-cell analysis for researchers worldwide.
-
PacBio to Acquire Apton Biosystems in Deal Up to $110 Million
August 2, 2023
Biotechnology
PacBio entered into an agreement to acquire Apton Biosystems, a Bay Area company developing a high-throughput short-read sequencer based on advanced optics, image processing, and clustering/chemistry. PacBio plans to integrate its Sequencing by Binding (SBB) short-read chemistry into Apton’s high-throughput instrument to accelerate development and commercialize a differentiated short-read platform.
-
Bionano Genomics Acquires BioDiscovery
October 12, 2021
Software
Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.
-
Twist Bioscience Acquires iGenomX
June 30, 2021
Biotechnology
Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.
-
Affymetrix Acquires Panomics for Approximately $73M
November 11, 2008
Biotechnology
Affymetrix Inc. agreed to acquire Panomics Inc., a Fremont, California–based provider of low- to mid-plex genetic and protein assay products, for approximately $73 million in cash. The purchase is intended to expand Affymetrix's product portfolio and enable a more complete genetic-analysis workflow—linking whole-genome microarray studies with targeted Panomics assays—and is expected to close by the end of 2008 subject to customary conditions.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.